Polaryx Therapeutics, Inc. Common Stock
- PLYX
- NASDAQ
- Biotechnology
- Small-Molecule Therapies
- Neurodegenerative Disease Drugs
$1.92
Today +2.13%Quote Oct 19, 2026, 08:00 PM UTC
−5.88%over the last month
Max drawdown −12.6%From 1-month high −10.7%3 months −17.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
11
Market value
$95.7M
Quote Oct 19
Floor
$1.90
1.0% below price
Resistance
$1.93
0.7% above price
Price vs analyst targets
Lowest target
$6.00Highest target
$7.00
$6.00Highest target
$7.00
- Price $1.92
- Average target $6.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 239% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PLYXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free